u/PepSmartOfficial

On the standard 2.4 mg dose the two year trial (STEP 5) put mean weight loss at 15.2 percent against 2.6 percent on placebo, and about a third of people lost 20 percent or more. The plateau everyone worries about is already in the data. Loss flattens around week 60 and then holds. Hitting a wall near month 15 is the normal shape of it, not a sign anything broke.

Stopping brings the weight back and this is the part people don't want to hear. In the STEP 1 extension, a year after stopping, people had regained about two thirds of what they lost, and the average went from 17.3 percent back to 5.6 percent. STEP 4 shows the other side. People who kept dosing lost another 7.9 percent, and the ones moved to placebo regained 6.9 percent. Staying on it is the maintenance plan. If 2.4 is rough there's a lower 1.7 mg dose that's an approved maintenance option, so you're not stuck picking between full dose and quitting.

side effects off the label: nausea around 44 percent, diarrhea 30 percent, vomiting 24 percent, constipation 24 percent. reads bad, but about 98 percent of the gut stuff was mild or moderate, it clusters during the dose increases, and it fades. slowing the ramp helps most, you're allowed to hold a dose an extra four weeks. smaller lower fat meals too. constipation is the one people underrate. hydrate first since you're probably a little dehydrated from eating and drinking less, then fiber, then move around, and a cheap PEG laxative if you need it. don't let it sit for a week.

wegovy isn't the strongest option now either. head to head (SURMOUNT-5) tirzepatide came out ahead, 20.2 percent vs 13.7 percent at 72 weeks. there's also a newer 7.2 mg high dose sitting around 20.7 percent and a 25 mg oral pill. and the cheap compounded route mostly closed, the FDA called the shortage resolved in february 2025, so a compound that's basically a copy isn't allowed anymore.

none of this means don't use it. it works. just go in knowing the plateau is normal, the weight comes back if you stop, and the dose ramp is where the side effects are.

full write up with all the sources is on my site: https://pepsmart.net/articles/wegovy-questions-answered (disclosure, pepsmart is mine)

not medical advice.

In the phase 2a trial (Sanyal et al., Nature Medicine 2024, n=98, people with obesity and fatty liver) liver fat dropped about 81% on 8 mg and about 82% on 12 mg at 24 weeks. Placebo basically didn't move.

Most people on the higher doses got their liver fat back under 5%, which is the normal range. 79% on 8 mg and 86% on 12 mg. Zero on placebo.

The reason it probably hits liver fat harder than semaglutide or tirzepatide is the glucagon arm those two don't have. Glucagon tells the liver to burn fat and make less of it. A fat-burning marker (beta-hydroxybutyrate) went up two to threefold with the dose.

here's the part that keeps getting left out. this was liver fat on an MRI, not a biopsy. the trial did not show that the inflammation and scarring (MASH, fibrosis) got better, and it couldn't. those are the things that actually make fatty liver dangerous.

it was small and hypothesis generating. not enriched for MASH, and it excluded people with advanced scarring. liver enzymes (ALT) didn't really change.

for context the two drugs actually approved for MASH with fibrosis (resmetirom and Wegovy) got there on biopsies from 888 patients showing resolution and fibrosis improvement. retatrutide has the fat number. it does not have the biopsy number yet, and it's still investigational.

so it drains the fat really well but the disease underneath is still unproven. the trials that biopsy the liver are what settle it.

not medical advice.

full writeup on my site:   https://pepsmart.net/articles/retatrutide-and-fatty-liver

Reconstitution is two steps and the second one is easy to misread.

1. Mix the powder with bac water to set a concentration in mg per mL. This part is just division.
2. Draw the volume for your dose and read it on the syringe.

The math:
10 mg vial + 1 mL bac water = 10 mg/mL
a 2 mg dose = 0.2 mL
on a U-100 insulin syringe, 100 units = 1 mL, so 0.2 mL = 20 units

the thing to keep straight is that units are volume, not mg. drawing to the 20 mark is 0.2 mL, not 20 mg. the FDA has flagged some 5x and 10x overdoses tied to reading units as mg or assuming the wrong concentration. worth planning the whole ladder before you mix too. at 10 mg/mL the 12 mg step is 1.2 mL and that won't fit in a 1 mL syringe, so you'd want a different concentration or a bigger syringe.

dosing. the trials started low and stepped up about every 4 weeks, roughly 2 to 4 to 8 to 12 mg. going faster mostly just adds nausea without getting you there sooner. once weekly because the half life is around 6 days.

full write up with a units table and two calculators (reconstitution and mg to units) is here:
https://pepsmart.net/articles/retatrutide-reconstitution-and-dosing

also free calculation tools here

https://pepsmart.net/calculator

if you're also on insulin or a sulfonylurea the dosing conversation is different.

i wrote this on our site so part of this is self promo, tried to make the post useful even if you never click. reta is investigational and this is educational, not medical advice.

One question that comes up fairly often is whether retatrutide can cause hypoglycemia.

Based on the mechanism of the drug and the clinical trial data available so far, the answer is generally no for people using retatrutide alone.

Retatrutide activates the GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP effects stimulate insulin release only when blood glucose is elevated (glucose-dependent), which is one reason this class of medications rarely causes hypoglycemia by itself. The glucagon component also works in the opposite direction by increasing blood glucose.

In Phase 2 obesity studies involving people without diabetes, gastrointestinal side effects and increased heart rate were reported, while hypoglycemia was not a prominent finding. Studies in people with type 2 diabetes also found retatrutide to be effective at lowering A1c with an overall favorable safety profile.

The main exception is if someone is also taking insulin or a sulfonylurea (such as glipizide, glimepiride, or glyburide). Those medications can cause hypoglycemia on their own, so combining them with retatrutide may require dose adjustments under the guidance of the prescribing clinician.

It’s also worth noting that because retatrutide can suppress appetite significantly, eating too little may cause symptoms like weakness or shakiness that can feel similar to low blood sugar. The only way to know for sure is to check a glucose reading.

Retatrutide is still an investigational medication, so this is based on its known mechanism and the published clinical trial data available so far.

I put together a more detailed review with citations to the published studies here if anyone wants to read further:

https://pepsmart.net/articles/retatrutide-and-low-blood-sugar

The room temp window is different for every one of these. straight from the FDA labels:

Ozempic: once it's in use, fine at room temp up to 86F for 56 days. or just keep it in the fridge.

Wegovy: 28 days at room temp.

Mounjaro and Zepbound, the single dose pens or vials: 21 days at room temp then toss it. and with Zepbound, once it's sat at room temp don't move it back to the fridge.

Rybelsus, the tablet: no fridge. keep it in the original bottle somewhere dry.

two things wreck these drugs.

freezing is the big one. every label says don't use it if it froze, even if it looks totally normal after it thaws. the back wall of your fridge and the spot right by the cooling vent can dip below freezing, so keep the pen on a middle shelf.

then heat. a hot car will do it. so will a windowsill in the sun, or a bag that ends up sitting next to a heater. leave it in the original carton and the carton works as a sunshade.

flying. put it in your carry-on. checked bags can freeze in the hold. TSA lets you bring medically necessary liquids over the 3.4oz limit if you declare them at the checkpoint, and gel ice packs are allowed even when they've melted, you just tell the officer. for a single travel day you usually don't need a cooler at all, the room temp window covers a flight plus a layover.

one more. if you're on a compounded vial instead of a branded pen, none of these day counts automatically apply. go by the beyond-use date your pharmacy printed on the vial.

disclosure, i run pepsmart. none of this is medical advice, just what the labels say, check yours.

full writeup with the label sources:
https://pepsmart.net/articles/glp1-storage-out-of-the-fridge

Drugs ending in "gliflozin" are SGLT2 inhibitors. They all work the same way. SGLT2 is a protein in your kidney that reabsorbs most of the glucose you filter out of your blood. These block it, so the extra sugar leaves in your urine instead of going back into circulation.

The five FDA-approved ones, generic to brand:

canagliflozin = Invokana
dapagliflozin = Farxiga
empagliflozin = Jardiance
ertugliflozin = Steglatro
bexagliflozin = Brenzavvy

sotagliflozin (Inpefa) is a close cousin that also blocks SGLT1 in the gut, so it's a dual inhibitor, not a pure SGLT2 one.

As a blood sugar drug the effect is modest. Around 0.5 to 1.0 percent off your A1c, plus a little weight and blood pressure. What made them a big deal was the outcome trials. Dapagliflozin and empagliflozin cut heart failure outcomes regardless of ejection fraction, and the class slows chronic kidney disease even in people without diabetes. That's why a cardiologist or nephrologist might put you on one even if your sugars are fine.

if you take one. genital yeast infections are the common side effect, sugary urine feeds yeast. the rarer serious one is ketoacidosis that can show up at near-normal blood sugar, so it's easy to miss, learn the symptoms. canagliflozin specifically carried a raised amputation signal in its trial, about 5.9 vs 2.8 per 1,000 patient-years, mostly toes and feet.

these aren't a GLP-1. GLP-1s work on appetite and the gut, these work at the kidney. plenty of people are on both.

not medical advice, just what the labels say.

full writeup:  https://pepsmart.net/articles/sglt2-inhibitors-canagliflozin-dapagliflozin

Ozempic babies have two pretty boring explanations and neither one is magic.

First one only applies to tirzepatide, which is Mounjaro and Zepbound. The drug slows down how fast your stomach empties. A birth control pill has to dissolve and absorb in there, so if things are moving slower the pill can get absorbed less completely. The Mounjaro label spells this out. A single 5mg dose dropped the peak level of the pill's estrogen by 59% and total exposure by about 20%.

The label also says the effect is biggest right after your first dose and after every dose increase. So the window where you least expect a problem is the window with the biggest hit. The fix the label gives is to use a backup like condoms or switch to a non-oral method for 4 weeks after you start and 4 weeks after each dose bump.

semaglutide is different. Ozempic and Wegovy actually studied the pill and found no meaningful effect on absorption, and those labels carry no contraceptive warning. so the "any GLP-1 kills your birth control" idea isn't true. it's specific to tirzepatide.

second reason has nothing to do with the pill. losing weight can restart ovulation. if you have PCOS or carry extra weight and your cycles were all over the place, taking weight off can get you ovulating again. this is old fertility advice, it predates these drugs by decades. the drug didn't do anything to your eggs, the weight loss restarted a system that was idling.

and if you do want to get pregnant, these aren't for use in pregnancy. the wegovy label says stop at least 2 months before trying because semaglutide hangs around a long time. so it's not a stop today try tomorrow thing.

none of this is a reason to panic or quit your meds. it's a reason to cover one specific window if pregnancy is a no for you right now.

I have a more in depth writeup on my site, link here https://pepsmart.net/articles/ozempic-babies-why-they-happen

A COA runs two different tests for two different questions. People usually only check one.

HPLC is the purity test. It's the main peak as a percent of the total area the detector saw, usually at 220 nm. It tells you how much of the sample is one dominant thing. It does not tell you that thing is the peptide you ordered. The wrong molecule can post a 99% number all day.

Mass spec is the identity test. It weighs the molecule, and in MS/MS it reads the sequence back. That's the question HPLC can't answer. A 99% pure sample is useless if the molecule is the wrong one.

So a COA with one purity number and no identity test is half a report. you want both on there.

a certificate the seller ran themselves, or paid for and chose to show you, isn't independent verification. even licensed drug makers can't just accept a supplier's cert at face value. the rule (21 CFR 211.84) makes them run their own identity test and keep checking the supplier over time. and you're sitting further down a rougher supply chain than a licensed manufacturer is.

the fakes you can catch without any chemistry:

lot number on the COA has to match the lot on your vial. a test only describes the batch it tested. recycled and doctored COAs both fall apart right here.

no chromatogram or spectrum attached, just a number typed on the page? there's no actual measurement there to look at.

take the report number to the lab that supposedly issued it and ask them to confirm it. a real lab can do that. a made-up cert can't survive the call.

when it really matters, send your own sample to an independent lab yourself. that's the one check nobody in the sale got to rig, because nobody picked the sample but you.

a COA covers one batch on one day. the next batch is its own test. it's a strong signal and nothing more than that.

disclosure: i run a peptide info site, not affiliated with any testing lab. not medical advice.

full writeup:   https://pepsmart.net/articles/how-to-read-a-peptide-coa

Microdosing GLP-1s: you take a small amount of semaglutide or tirzepatide, pay less, get fewer side effects, and still lose the weight. Here's where the actual evidence sits.

The appeal makes sense on paper. Less drug can mean lower cost and milder side effects, and plenty of people want a small maintenance dose after they've already hit their goal.

The problem is nobody has actually tested it. No trial has studied doses below the FDA-approved ones. Whether you still get the benefit at those tiny amounts hasn't been measured, and one university physician put it as basically remaining to be seen.

Worth knowing that starting low isn't some hack people discovered. The approved schedules already start small and ramp up slowly. Semaglutide begins at 0.25 mg and works up to 2.4 mg. Tirzepatide starts at 2.5 mg. A doctor keeping you on a low individualized dose is just normal care, not microdosing.

the thing that actually puts people in the hospital is the source, not the small number. microdosing usually means compounded product you're measuring out yourself, and the FDA has logged hospitalizations from dosing errors and people mixing up mL, mg, and "units."

so the honest split is this. a doctor lowering your dose under supervision is fine. buying compounded product off a website to self-microdose has no evidence it works and a real risk of you screwing up the measurement.

full write-up with the dosing schedules and sources: https://pepsmart.net/articles/glp1-microdosing-what-it-is

Hair loss does show up in the GLP-1 trials but it's uncommon. On Wegovy 3% of adults reported it vs 1% on placebo. On Zepbound it was around 4 to 5% vs 1%.

Women report it way more than men. In the Zepbound trials it was 7.1% in women vs 0.5% in men.

What you're almost certainly dealing with is telogen effluvium. That's the temporary shedding that follows fast weight loss, low protein intake, and physical stress on the body. The Zepbound label ties it to the weight loss itself, not the drug.

The timing is what makes it feel alarming. The shedding usually doesn't start until 2 to 3 months after the change, so by the time you notice it you've been on the med a while and it feels out of nowhere. It then recovers over the months that follow.

it grows back. once your weight and your eating level out the density tends to come back.

stuff that helps: get enough protein, slow the pace down if you have the option, and wait it out. go see a doctor if you get actual bald patches or it keeps going past a few months. they can check your iron and thyroid since those cause shedding too and are easy to rule out.

full write-up with the label figures and sources: https://pepsmart.net/articles/ozempic-hair-loss-why-it-happens. --heads up im the owner of the site

Ozempic face is the gaunt or older look some people get after losing weight on a GLP-1.

The medication isn't doing anything to your face directly. you lose the fat that keeps a face looking full, and the face shows it before the rest of the body catches up.

A 2025 systematic review looked for any sign that GLP-1s strip facial fat on purpose and found none. you get the same effect from bariatric surgery or any other fast weight loss. the term came from a dermatologist in New York around 2023, after a run of patients who felt good about losing the weight but thought they looked older for it.

what's going on under the skin is pretty simple. fat in the cheeks and temples is part of what gives a face its shape, so when it drops fast those areas hollow out. skin that stretched to cover more weight doesn't tighten back at the same speed, so it sags a little. rapid loss also tends to pull down collagen and elastin, which doesn't help.

it shows up most in the middle of the face. cheeks, temples, under the eyes, along the jaw. some people end up looking around five years older than they did before.

if you want to limit it, slower loss helps, somewhere in the range of 1 to 2 lb a week instead of going as fast as possible. enough protein keeps more muscle on you, water helps the skin, and fillers or skin treatments are there if you decide you want them. and if the weight comes back later the face usually fills back in too.

full write-up with the sources: https://pepsmart.net/articles/ozempic-face-what-it-is-and-why-it-happens

for research and educational purposes only. not medical advice.

Most people gain weight back after stopping a GLP-1, but not all of it. That holds up pretty well across the trials that deliberately took people off the drug.

Three worth knowing:

STEP 1 extension (semaglutide). People dropped about 17% over 68 weeks and then came off. A year later they'd put back roughly two thirds of it, landing around 5.6% under their starting weight.

STEP 4 (semaglutide). Everyone lost about 11% in a 20-week run-in. Then half stayed on and half went to placebo. The group that stayed on lost another 8% or so. The group that came off gained back about 7%.

SURMOUNT-4 (tirzepatide). About 21% lost over 36 weeks, then continue or stop. The ones who continued kept losing a little. The placebo group put back around 14% over the following year.

The reason is mostly appetite. These drugs turn the hunger down, so while you're on it eating less doesn't take much effort. Come off and the appetite and the food noise come back, and the weight tends to follow. The trials basically treat obesity as something the drug manages while you take it.

One thing that surprised me is how much people kept. Most of them were still down a fair bit a year out, just not at their lowest point. Keep in mind these are group averages, so any one person can land well above or below that. And there's no taper that's been shown to make it a one-and-done course, which is the kind of thing you'd want to know going in.

Not medical advice, just what the trials say. I wrote the whole thing up with every source (STEP 1 extension, STEP 4, SURMOUNT-4, and the Wegovy label) here:

https://pepsmart.net/articles/what-happens-when-you-stop-a-glp1

Nausea is the most common side effect on both drugs and it mostly hits while you're climbing the dose, not once you've leveled off. On semaglutide (Wegovy) about 44% of people reported it vs 16% on placebo. On tirzepatide (Zepbound) about 25 to 29% vs 8%. Both FDA labels say the gut effects rose during dose escalation and then eased, which is why you start low and step up slow. The stuff that actually helps is boring: smaller meals more often, backing off greasy high-fat food, keeping fluids up, fiber for the constipation and diarrhea swings, and a 10 to 15 minute walk after eating, which improved belching, gas, and fullness in one trial.

fatigue is on the label too, about 11% on sema vs 5% placebo, usually early and usually tied to suddenly eating and drinking a lot less, so don't let a quiet appetite turn into skipped meals. injection-site reactions are uncommon on sema (1.4% vs 1.0%) and a bit more common on tirz (6 to 8% vs 2%), so rotate sites, let the pen warm up, don't reuse needles. and on the "couldn't handle sema, should i switch to tirz" question, they're cousins not opposites. the head to head trial (SURMOUNT-5) found both are gut-heavy and both peak during the climb. some people do feel better on one, but it's a clinician call, and a slower climb usually does more than swapping the molecule.

when it's not just a side effect: vomiting you can't keep down, signs of dehydration, severe belly pain (especially pain that bores through to your back), or no bowel movement with a swollen belly. that's a phone call, not a food tweak.

educational, not medical advice. sources are the FDA prescribing info for semaglutide and tirzepatide plus the NEJM head to head trial. full writeup with the per-effect numbers and a sema vs tirz table: https://pepsmart.net/articles/glp1-side-effects-what-helps

Oral and injectable BPC-157 are not interchangeable, and which one makes sense depends on what you're trying to fix.

BPC-157 survives stomach acid. It stays intact in human gastric juice for over 24 hours, while growth factors like EGF get torn apart in minutes. That part is real, and it's where the whole oral pitch comes from.

Surviving your stomach is not the same as getting into your blood. Oral semaglutide (Rybelsus) is the same molecule as the injectable, engineered with a dedicated absorption enhancer (SNAC), strict empty-stomach dosing, and years of formulation work, and it still only reaches about 0.4 to 1 percent bioavailability. A plain BPC-157 capsule has none of that. It's bare peptide in a shell.

Almost all the oral BPC-157 rat studies measure local gut healing: gastric ulcers, intestinal anastomosis, colitis models. In those the peptide is sitting on the tissue it's meant to heal, so it doesn't need to get absorbed to work on a gut lining it's already touching. a tendon in your shoulder needs systemic absorption that has never been measured in a human. and even in the gut, where oral has its best case, a head to head rat study found intramuscular injection healed better and at a lower dose than intragastric.

where it lands:

• gut stuff: oral has the strongest case, still rodent only.
• tendons, joints, anything systemic: oral is the weakest option, injection at least gets you higher exposure.
• either way: no human pharmacokinetics, no completed human trial, FDA 503A category 2, flat WADA ban if you get tested.

full writeup with all the citations (PubMed, DailyMed, FDA, WADA) is below. For research and educational purposes only. Not medical advice.

https://pepsmart.net/articles/bpc-157-oral-vs-injectable

All numbers below are the 12 mg dose, averaged from the published trials.

Dosing ramps from 2 to 4 mg up to 12 over the first several weeks. GI side effects are heaviest during that ramp and ease off once you're at the top dose.

Phase 2 (NEJM, 338 people): about 17.5% at 24 weeks, 24.2% by week 48. Still trending down at 48 when the study ended.

Phase 3 (TRIUMPH-1, 2,339 people, results this year): about 28% at 80 weeks for people who stayed on it, about 25% if you count everyone who started. Extension arm reached roughly 30% at 104 weeks.

Side effects, from the trials:

mostly GI, nausea, diarrhea, vomiting, constipation. mild to moderate, concentrated in the ramp phase. pooled data put nausea around 4x placebo at the higher doses. discontinuation from side effects was 6 to 16% in phase 2, and 11.3% on 12 mg in TRIUMPH-1 against 4.9% on placebo.

still investigational, not FDA approved, and Lilly only offers it through trials right now. side effect rates are self-reported in-trial.

full writeups with every number sourced, side effects in a separate one: https://pepsmart.net/articles/retatrutide-weight-loss-timeline https://pepsmart.net/articles/retatrutide-side-effects

research and educational only, not medical advice. I help run that site.

If you started Ozempic, Wegovy, Mounjaro, or Zepbound and got burps that smell like rotten eggs, you're not broken and you're not alone. It's one of the most talked-about side effects right now.

Short version: these meds slow your stomach down on purpose, so sulfur-rich, fatty food sits there longer and your gut bacteria turn it into hydrogen sulfide gas. That gas is the rotten-egg smell.

Good news is the fix is mostly on your plate. For a day or two:

• Ease off the big sulfur hitters: eggs, red meat, garlic, onions, and big piles of broccoli or cabbage
• Go easy on fried and greasy meals
• Keep meals smaller, chew slowly, and take a 10-minute walk after you eat

most people find the smell settles as the food load lightens. if the burps ever come with severe pain or vomiting you can't keep down, that's a call to your clinician, not a food tweak.

we broke down exactly what to eat and what to cut for the next 24 hours, with the research behind it, here:https://pepsmart.net/articles/glp1-sulfur-burps-what-to-eat

For research and educational purposes only. Not medical advice.

A few weeks into reta, the common report is the same: the constant food chatter just goes quiet. Here's what the research actually says, which is a little more complicated than the hype.

Short version: the quiet is real and it tracks with the biology, but almost all the measured "cravings went quiet" data is on semaglutide, not reta. Reta's own phase 2 trial mostly measured weight (about 24% at the top dose by 48 weeks), not food noise. The quiet still shows up on reta because it hits the same GLP-1 target semaglutide does, plus two more (GIP and glucagon), and that's the brain wiring food noise lives in.

Two things to keep in mind. Reta is still investigational and not approved (phase 3 right now), and the quiet usually comes back once you stop.

Full write-up with sources here: https://pepsmart.net/articles/retatrutide-and-food-noise

disclaimer: I own the website